Ke. Warren et al., Proton magnetic resonance spectroscopic imaging in children with recurrentprimary brain tumors, J CL ONCOL, 18(5), 2000, pp. 1020-1026
Purpose: Proton magnetic resonance spectroscopic imaging (H-1-MRSI) is a no
ninvasive technique for spatial characterization of biochemical markers in
tissues. We measured the relative tumor concentrations of these biochemical
markers in children with recurrent brain tumors and evaluated their potent
ial prognostic significance.
Patients and Methods: H-1-MRSI was performed on 27 children with recurrent
primary brain tumors referred to our institution for investigational drug t
rials, Diagnoses included high-grade glioma (n = 10), brainstem glioma (n =
7), medulloblastoma/peripheral neuroectodermal tumor (n = 6), ependymoma (
n = 3), and pineal germinoma (n = 1). H-1-MRSI was performed on 1.5-T magne
tic resonance imagers before treatment. The concentrations of choline (Cho)
and N-acetyl-aspartate (NAA) in the tumor and normal brain were quantified
using a multislice multivoxel method, and the maximum Cho:NAA ratio was de
termined for each patient's tumor.
Results: The maximum Cho:NAA ratio ranged from 1.1 to 13.2 (median, 4.5); t
he Cho:NAA ratio in areas of normal-appearing brain tissue was less than 1.
0, The maximum Cho:NAA ratio for each histologic subtype varied considerabl
y; approximately equal numbers of patients within each tumor type had maxim
um Cho: NAA ratios above and below the median. Patients with a maximum Cho:
NAA ratio greater than 4.5 had a median survival of 22 weeks, and all 13 pa
tients died by 63 weeks. Patients with a Cho:NAA ratio less than or equal t
o 4.5 had a projected survival of more than 50% at 63 weeks. The difference
was statistically significant (P = .0067, log-rank test).
Conclusion: The maximum tumor Cho:NAA ratio seems to be predictive of outco
me in children with recurrent primary brain tumors and should be evaluated
as a prognostic indicator in newly diagnosed childhood brain tumors. J Clin
Oncol 18:1020-1026, (C) 2000 by American Society of Clinical Oncology.